Arts & Sciences Brown School McKelvey School of Engineering School of Law School of Medicine Weekly Publications

WashU weekly Neuroscience publications

“Critical tests of the continuous dual-process model of recognition” (2021) Cognition

Critical tests of the continuous dual-process model of recognition
(2021) Cognition, 215, art. no. 104827, . 

Cha, J., Dobbins, I.G.

Department of Psychological and Brain Sciences, Washington University in Saint Louis, United States

Abstract
Dual process recognition models assume recognition depends upon context recollection and/or item familiarity. While most assume recollection is more highly valued or weighted than familiarity during judgment, we tested a continuous dual process (CDP) model that instead assumes recollection and familiarity are equally weighted during recognition judgment. Experiments 1a and 1b used a joint rating scale in which each probe was rated for recollection and familiarity strength, which were then used to predict overall recognition confidence. In both, recollection dominated familiarity such that familiarity ratings were only predictive of confidence when recollection ratings were relatively weaker. In contrast, when recollection ratings were stronger, familiarity made no contribution to recognition confidence. Experiment 2 used a different, bifurcated rating scale previously demonstrating that strong ratings of familiarity can lead to better recognition yet worse contextual source memory than weak ratings of recollection. However, the current study failed to find this dissociation, instead demonstrating that weak recollection ratings were as or more accurate than the strongest familiarity ratings in both recognition and source memory. Replacing the CDP model equal weighting decision rule with one incorporating a strong relative preference for recollection over familiarity yielded simulation data more consistent with the empirical data and is more optimal if recollection is in fact more diagnostic of recognition than familiarity. Overall, these findings suggest that observers have a strong preference for relying on recollection over familiarity during recognition, presumably because it better situates the probe within a specific episode. © 2021 Elsevier B.V.

Author Keywords
Dual-process model;  Familiarity;  Recognition;  Recollection;  Signal-detection theory

Document Type: Article
Publication Stage: Final
Source: Scopus

“Meaningful associations in the adolescent brain cognitive development study” (2021) NeuroImage

Meaningful associations in the adolescent brain cognitive development study
(2021) NeuroImage, 239, art. no. 118262, . 

Dick, A.S.a , Lopez, D.A.b , Watts, A.L.c , Heeringa, S.d , Reuter, C.e , Bartsch, H.f , Fan, C.C.g , Kennedy, D.N.h , Palmer, C.i , Marshall, A.j , Haist, F.k , Hawes, S.a , Nichols, T.E.l , Barch, D.M.m , Jernigan, T.L.h , Garavan, H.n , Grant, S.o , Pariyadath, V.o , Hoffman, E.p , Neale, M.q , Stuart, E.A.r , Paulus, M.P.s , Sher, K.J.c , Thompson, W.K.e g

a Department of Psychology and Center for Children and Families, Florida International University, Miami, FL, United States
b Division of Epidemiology, Department of Public Health Sciences, University of Rochester Medical Center, Rochester, NY 14642, United States
c Department of Psychology, University of MissouriMO, United States
d Institute for Social Research, University of Michigan, Ann Arbor, MI 48109, United States
e Herbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego, La Jolla, CA 92093, United States
f Mohn Medical Imaging and Visualization Center, Department of Radiology, Haukeland University Hospital, Bergen, Norway
g Population Neuroscience and Genetics Lab, University of California, San Diego, La Jolla, CA 92093, United States
h Department of Psychiatry, University of Massachusetts Medical SchoolMA 01604, United States
i Center for Human Development, University of California, San Diego, La Jolla, CA 92093, United States
j Children’s Hospital Los Angeles, and the Department of Pediatrics, University of Southern California, Los Angeles, CA, United States
k Department of Radiology, University of California, San Diego, La Jolla, CA 92093, United States
l Oxford Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom
m Departments of Psychological & Brain Sciences, Psychiatry and Radiology, Washington University, St. Louis, MO 63130, United States
n Department of Psychiatry, University of Vermont, Burlington, VT 05405, United States
o Behavioral and Cognitive Neuroscience Branch, Division of Neuroscience and Behavior, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, United States
p National Institute on Drug Abuse, National Institutes of Health, Department of Heatlh and Human Services, Bethesda, MD, United States
q Department of Psychiatry, Virginia Commonwealth University, Richmond, VA 23298, United States
r Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, United States
s Laureate Institute for Brain Research, Tulsa, OK, United States

Abstract
The Adolescent Brain Cognitive Development (ABCD) Study is the largest single-cohort prospective longitudinal study of neurodevelopment and children’s health in the United States. A cohort of n = 11,880 children aged 9–10 years (and their parents/guardians) were recruited across 22 sites and are being followed with in-person visits on an annual basis for at least 10 years. The study approximates the US population on several key sociodemographic variables, including sex, race, ethnicity, household income, and parental education. Data collected include assessments of health, mental health, substance use, culture and environment and neurocognition, as well as geocoded exposures, structural and functional magnetic resonance imaging (MRI), and whole-genome genotyping. Here, we describe the ABCD Study aims and design, as well as issues surrounding estimation of meaningful associations using its data, including population inferences, hypothesis testing, power and precision, control of covariates, interpretation of associations, and recommended best practices for reproducible research, analytical procedures and reporting of results. © 2021 The Author(s)

Author Keywords
Adolescent brain cognitive development study;  Covariate Adjustments;  Effect Sizes;  Genetics;  Hypothesis testing;  Population neuroscience;  Reproducibility

Funding details
National Institutes of HealthNIHU01DA041022, U01DA041025, U01DA041028, U01DA041048, U01DA041089, U01DA041093, U01DA041106, U01DA041117, U01DA041120, U01DA041134, U01DA041148, U01DA041156, U01DA041174, U01DA050987, U01DA050988, U01DA050989, U01DA051016, U01DA051018, U01DA051037, U01DA051038, U01DA051039, U24DA041147
National Institute of Mental HealthNIMH
National Institute on Drug AbuseNIDAU24DA041123

Document Type: Review
Publication Stage: Final
Source: Scopus

“Effect of statins on functional outcome and mortality following aneurysmal subarachnoid hemorrhage – Results of a meta-analysis, metaregression and trial sequential analysis” (2021) Clinical Neurology and Neurosurgery

Effect of statins on functional outcome and mortality following aneurysmal subarachnoid hemorrhage – Results of a meta-analysis, metaregression and trial sequential analysis
(2021) Clinical Neurology and Neurosurgery, 207, art. no. 106787, . 

Bohara, S.a , Gaonkar, V.B.a , Garg, K.a , Rajpal, P.M.S.b , Singh, P.K.a , Singh, M.a , Suri, A.a , Chandra, P.S.a , Kale, S.S.a

a Department of Neurosurgery, All India Institute of medical SciencesNew Delhi, India
b Department of Anesthesia, Washington University in St. LouisMO, United States

Abstract
Objective: Cerebral vasospasm (CVS) and delayed ischemic neurological deficits (DIND) are a common cause of morbidity following aneurysmal subarachnoid hemorrhage (SAH). Statins have been shown to decrease CVS. The objective of this article was to ascertain the effect of statins on functional outcome and mortality following aneurysmal SAH by performing meta-analysis. Methods: A comprehensive search of different databases was performed to retrieve randomized controlled trials. Meta-analysis with subgroup analysis and metaregression was done. Trial sequential analysis (TSA) was performed to determine if the cumulative sample size was appropriately powered for the obtained pooled effect values and to avoid random error. Results: Twelve articles were selected for meta-analysis. Pooled OR for the change in favorable outcome, mortality, CVS, DIND and elevated transaminases was 1.07 (p = 0.55), 0.78 (p = 0.17), 0.58 (p = 0.0004), 0.54 (p = 0.0293) and 0.68 (p = 0.1774) respectively. Further, subgroup analysis and metaregression showed that the use of different statin or dose did not result in significant variation in results in the parameters studied. TSA showed that more trials and patients are required to reach to a definitive conclusion regarding any effect on statins on functional outcome and mortality as the current studies neither reached the level of confidence nor crossed the futility boundary. Conclusion: Use of statins in patients with aneurysmal SAH resulted in marginal but non-significant favorable impact on functional outcome and mortality. TSA showed that more studies are required to get conclusive evidence in this regard. © 2021

Author Keywords
Meta-analyses;  Statins;  Subarachnoid hemorrhage;  Trial Sequential analysis;  Vasospasm

Document Type: Review
Publication Stage: Final
Source: Scopus

“Sneezing reflex is mediated by a peptidergic pathway from nose to brainstem” (2021) Cell

Sneezing reflex is mediated by a peptidergic pathway from nose to brainstem
(2021) Cell, 184 (14), pp. 3762-3773.e10. 

Li, F.a , Jiang, H.a , Shen, X.a , Yang, W.a , Guo, C.a , Wang, Z.a , Xiao, M.a , Cui, L.b , Luo, W.b , Kim, B.S.a c , Chen, Z.a c d e , Huang, A.J.W.f , Liu, Q.a c f g

a Department of Anesthesiology, Center for the Study of Itch and Sensory Disorders, and Washington University Pain Center, Washington University School of Medicine, St. Louis, MO 63110, United States
b Department of Neuroscience, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, United States
c Division of Dermatology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, United States
d Department of Psychiatry, Washington University School of Medicine, St. Louis, MO 63110, United States
e Department of Developmental Biology, Washington University School of Medicine, St. Louis, MO 63110, United States
f Department of Ophthalmology & Visual Sciences, Washington University School of Medicine, St. Louis, MO 63110, United States
g Department of Neuroscience, Washington University School of Medicine, St. Louis, MO 63110, United States

Abstract
Sneezing is a vital respiratory reflex frequently associated with allergic rhinitis and viral respiratory infections. However, its neural circuit remains largely unknown. A sneeze-evoking region was discovered in both cat and human brainstems, corresponding anatomically to the central recipient zone of nasal sensory neurons. Therefore, we hypothesized that a neuronal population postsynaptic to nasal sensory neurons mediates sneezing in this region. By screening major presynaptic neurotransmitters/neuropeptides released by nasal sensory neurons, we found that neuromedin B (NMB) peptide is essential for signaling sneezing. Ablation of NMB-sensitive postsynaptic neurons in the sneeze-evoking region or deficiency in NMB receptor abolished the sneezing reflex. Remarkably, NMB-sensitive neurons further project to the caudal ventral respiratory group (cVRG). Chemical activation of NMB-sensitive neurons elicits action potentials in cVRG neurons and leads to sneezing behavior. Our study delineates a peptidergic pathway mediating sneezing, providing molecular insights into the sneezing reflex arc. © 2021 Elsevier Inc.

Author Keywords
caudal ventral respiratory group;  nasal sensory neurons;  neuropeptide;  sneeze;  sneeze-evoking region

Funding details
National Institutes of HealthNIHR01AI125743, R01EY024704
National Institute of Arthritis and Musculoskeletal and Skin DiseasesNIAMSK08-AR065577, R01AR070116, R01AR077007
Doris Duke Charitable FoundationDDCF
Boehringer IngelheimBI
American Skin AssociationASA
Pfizer
AbbVie
Cidara Therapeutics
Kiniksa Pharmaceuticals

Document Type: Article
Publication Stage: Final
Source: Scopus

“Mechanical and mechanothermal effects of focused ultrasound elicited distinct electromyographic responses in mice” (2021) Physics in Medicine and Biology

Mechanical and mechanothermal effects of focused ultrasound elicited distinct electromyographic responses in mice
(2021) Physics in Medicine and Biology, 66 (13), art. no. 135005, . 

Baek, H.a , Yang, Y.a , Pacia, C.P.a , Xu, L.a , Yue, Y.a , Bruchas, M.R.b , Chen, H.a c

a Department of Biomedical Engineering, Washington University in St. Louis, Saint Louis, MO 63130, United States
b Department of Anesthesiology and Pain Medicine, Center for Neurobiology of Addiction, Pain and Emotion, University of Washington, Seattle, WA 98195, United States
c Department of Radiation Oncology, Washington University School of Medicine, Saint Louis, MO 63108, United States

Abstract
The objective of this study was to compare focused ultrasound (FUS) neuromodulation-induced motor responses under two physical mechanisms: mechanical and mechanothermal effects. Mice were divided into two groups. One group was subjected to short-duration FUS stimulation (0.3 s) that induced mechanical effects (mechanical group). The other group underwent long-duration FUS stimulation (15 s) that produced not only mechanical but also thermal effects (mechanothermal group). FUS was targeted at the deep cerebellar nucleus in the cerebellum to induce motor responses, which were evaluated by recording the evoked electromyographic (EMG) signals and tail movements. Brain tissue temperature rise associated with the FUS stimulation was quantified by noninvasive magnetic resonance thermometry in vivo. Temperature rise was negligible for the mechanical group (0.2 °C ± 0.1 °C) but did rise within the range of 0.6 °C ± 0.2 °C-3.3 °C ± 0.9 °C for the mechanothermal group. The elongated FUS beam also induced heating in the dorsal brain (below the top skull) and ventral brain (above the bottom skull) along the beam path for the mechanothermal group. Both mechanical and mechanothermal groups achieved successful FUS neuromodulation. EMG response latencies were within the range of 0.03-0.1 s at different intensity levels for the mechanical group. The mechanothermal effect of FUS could induce both short-latency EMG (0.2-1.4 s) and long-latency EMG (8.7-13.0 s) under the same intensity levels as the mechanical group. The different temporal dynamics of evoked EMG suggested that FUS-induced mechanical and mechanothermal effects could evoke different responses in the brain. © 2021 Institute of Physics and Engineering in Medicine.

Author Keywords
electromyography;  focused ultrasound;  motor response;  neuromodulation

Funding details
National Institutes of HealthNIHR01MH116981
National Institute of Biomedical Imaging and BioengineeringNIBIBR01EB027223, R01EB030102

Document Type: Article
Publication Stage: Final
Source: Scopus

“Patient-derived iPSC-cerebral organoid modeling of the 17q11.2 microdeletion syndrome establishes CRLF3 as a critical regulator of neurogenesis” (2021) Cell Reports

Patient-derived iPSC-cerebral organoid modeling of the 17q11.2 microdeletion syndrome establishes CRLF3 as a critical regulator of neurogenesis
(2021) Cell Reports, 36 (1), art. no. 109315, . 

Wegscheid, M.L., Anastasaki, C., Hartigan, K.A., Cobb, O.M., Papke, J.B., Traber, J.N., Morris, S.M., Gutmann, D.H.

Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, United States

Abstract
Neurodevelopmental disorders are often caused by chromosomal microdeletions comprising numerous contiguous genes. A subset of neurofibromatosis type 1 (NF1) patients with severe developmental delays and intellectual disability harbors such a microdeletion event on chromosome 17q11.2, involving the NF1 gene and flanking regions (NF1 total gene deletion [NF1-TGD]). Using patient-derived human induced pluripotent stem cell (hiPSC)-forebrain cerebral organoids (hCOs), we identify both neural stem cell (NSC) proliferation and neuronal maturation abnormalities in NF1-TGD hCOs. While increased NSC proliferation results from decreased NF1/RAS regulation, the neuronal differentiation, survival, and maturation defects are caused by reduced cytokine receptor-like factor 3 (CRLF3) expression and impaired RhoA signaling. Furthermore, we demonstrate a higher autistic trait burden in NF1 patients harboring a deleterious germline mutation in the CRLF3 gene (c.1166T>C, p.Leu389Pro). Collectively, these findings identify a causative gene within the NF1-TGD locus responsible for hCO neuronal abnormalities and autism in children with NF1. © 2021 The Author(s)

Author Keywords
autism;  brain development;  cerebral organoids;  CRLF3;  human induced pluripotent stem cells;  intellectual disability;  microdeletion;  neurofibromatosis type 1;  neurons;  RAS

Funding details
National Institutes of HealthNIH1-R35-NS07211-01
National Cancer InstituteNCIP30-CA091842
Children’s Tumor FoundationCTF2018-01-003

Document Type: Article
Publication Stage: Final
Source: Scopus

“Image segmentation for neuroscience: Lymphatics” (2021) JPhys Photonics

Image segmentation for neuroscience: Lymphatics
(2021) JPhys Photonics, 3 (3), art. no. e035004, . 

Tabassum, N.a f , Wang, J.a , Ferguson, M.b , Herz, J.c , Dong, M.d , Louveau, A.e , Kipnis, J.c , Acton, S.T.a

a Department of Electrical and Computer Engineering, University of Virginia, Charlottesville, VA, United States
b Department of Computer Science, University of Virginia, Charlottesville, VA, United States
c Department of Pathology and Immunology, Washington University School of Medicine in St Louis, St Louis, MO, United States
d Internal Medicine, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, United States
e Lerner Research Institute, Cleveland Clinic, Cleveland, OH, United States
f Analytic Server R&D Testing, SAS Institute, Cary, NC 27513, United States

Abstract
A recent discovery in neuroscience prompts the need for innovation in image analysis. Neuroscientists have discovered the existence of meningeal lymphatic vessels in the brain and have shown their importance in preventing cognitive decline in mouse models of Alzheimer s disease. With age, lymphatic vessels narrow and poorly drain cerebrospinal fluid, leading to plaque accumulation, a marker for Alzheimer s disease. The detection of vessel boundaries and width are performed by hand in current practice and thereby suffer from high error rates and potential observer bias. The existing vessel segmentation methods are dependent on user-defined initialization, which is time-consuming and difficult to achieve in practice due to high amounts of background clutter and noise. This work proposes a level set segmentation method featuring hierarchical matting, LyMPhi, to predetermine foreground and background regions. The level set force field is modulated by the foreground information computed by matting, while also constraining the segmentation contour to be smooth. Segmentation output from this method has a higher overall Dice coefficient and boundary F1-score compared to that of competing algorithms. The algorithms are tested on real and synthetic data generated by our novel shape deformation based approach. LyMPhi is also shown to be more stable under different initial conditions as compared to existing level set segmentation methods. Finally, statistical analysis on manual segmentation is performed to prove the variation and disagreement between three annotators. © JPhys Complexity 2021. All rights reserved.

Author Keywords
data augmentation;  deformation transfer;  level-set segmentation;  manual segmentation;  meningeal lymphatics;  shape transform;  vessel segmentation

Funding details
University of VirginiaUV

Document Type: Article
Publication Stage: Final
Source: Scopus

“Targeting the gut to treat multiple sclerosis” (2021) Journal of Clinical Investigation

Targeting the gut to treat multiple sclerosis
(2021) Journal of Clinical Investigation, 131 (13), art. no. e143774, . 

Ghezzi, L.a b , Cantoni, C.a , Pinget, G.V.c , Zhou, Y.d , Piccio, L.a e f

a Department of Neurology, School of Medicine, Washington University in St. Louis, St. Louis, MS, United States
b University of Milan, Milan, Italy
c Charles Perkins Centre, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia
d Department of Medicine, School of Medicine, UConn Health, Farmington, CT, United States
e Brain and Mind Centre, School of Medical Sciences, University of Sydney, Sydney, NSW, Australia
f Hope Center for Neurological Disorders, Department of Neurology, School of Medicine, Washington University in St. Louis, St. Louis, MS, United States

Abstract
The gut-brain axis (GBA) refers to the complex interactions between the gut microbiota and the nervous, immune, and endocrine systems, together linking brain and gut functions. Perturbations of the GBA have been reported in people with multiple sclerosis (pwMS), suggesting a possible role in disease pathogenesis and making it a potential therapeutic target. While research in the area is still in its infancy, a number of studies revealed that pwMS are more likely to exhibit altered microbiota, altered levels of short chain fatty acids and secondary bile products, and increased intestinal permeability. However, specific microbes and metabolites identified across studies and cohorts vary greatly. Small clinical and preclinical trials in pwMS and mouse models, in which microbial composition was manipulated through the use of antibiotics, fecal microbiota transplantation, and probiotic supplements, have provided promising outcomes in preventing CNS inflammation. However, results are not always consistent, and large-scale randomized controlled trials are lacking. Herein, we give an overview of how the GBA could contribute to MS pathogenesis, examine the different approaches tested to modulate the GBA, and discuss how they may impact neuroinflammation and demyelination in the CNS. © 2021, American Society for Clinical Investigation.

Funding details
2014/R/15
W81XWH-14-1-0156
National Institute of Neurological Disorders and StrokeNINDS
National Multiple Sclerosis SocietyFG-1907-34474, TA-1805-31003
Fondazione Italiana Sclerosi MultiplaFISM
Associazione Italiana Sclerosi MultiplaAISMFISM 2018/B/1

Document Type: Review
Publication Stage: Final
Source: Scopus

“Loss of C2orf69 defines a fatal autoinflammatory syndrome in humans and zebrafish that evokes a glycogen-storage-associated mitochondriopathy” (2021) American Journal of Human Genetics

Loss of C2orf69 defines a fatal autoinflammatory syndrome in humans and zebrafish that evokes a glycogen-storage-associated mitochondriopathy
(2021) American Journal of Human Genetics, 108 (7), pp. 1301-1317. 

Wong, H.H.a , Seet, S.H.a , Maier, M.b , Gurel, A.c , Traspas, R.M.b , Lee, C.a d , Zhang, S.c , Talim, B.e , Loh, A.Y.T.a , Chia, C.Y.b , Teoh, T.S.b , Sng, D.b , Rensvold, J.f g , Unal, S.h i , Shishkova, E.j k , Cepni, E.l , Nathan, F.M.m , Sirota, F.L.n , Liang, C.c , Yarali, N.o , Simsek-Kiper, P.O.p , Mitani, T.q , Ceylaner, S.r , Arman-Bilir, O.o , Mbarek, H.s , Gumruk, F.h i , Efthymiou, S.t , Uğurlu Çi̇men, D.u , Georgiadou, D.b , Sotiropoulou, K.a , Houlden, H.v , Paul, F.a , Pehlivan, D.q w x , Lainé, C.y z , Chai, G.aa ab , Ali, N.A.b , Choo, S.C.b , Keng, S.S.a , Boisson, B.y z ac , Yılmaz, E.u , Xue, S.a ad , Coon, J.J.g j k ae , Ly, T.T.N.a ad , Gilani, N.af , Hasbini, D.ag , Kayserili, H.u , Zaki, M.S.ah , Isfort, R.J.ai , Ordonez, N.aj , Tripolszki, K.aj , Bauer, P.aj , Rezaei, N.ak al , Seyedpour, S.an , Khotaei, G.T.am , Bascom, C.C.ai , Maroofian, R.t , Chaabouni, M.an , Alsubhi, A.ao ap , Eyaid, W.ao ap , Işıkay, S.aq , Gleeson, J.G.aa ab , Lupski, J.R.q w x ar , Casanova, J.-L.y z ac as at , Pagliarini, D.J.f g j au av aw , Akarsu, N.A.c , Maurer-Stroh, S.n , Cetinkaya, A.c , Bertoli-Avella, A.aj , Mathuru, A.S.a m ax , Ho, L.a d , Bard, F.A.a , Reversade, B.a b u ay

a Institute of Molecular and Cell Biology, A<sup></sup>STAR, Biopolis, Singapore, 138673, Singapore
b Laboratory of Human Genetics & Therapeutics, Genome Institute of Singapore, A<sup>
</sup>STAR, Biopolis, Singapore, 138672, Singapore
c Department of Medical Genetics, Faculty of Medicine, Hacettepe University, Ankara, 06230, Turkey
d Cardiovascular and Metabolic Diseases, Duke-NUS Medical School, Singapore, 169857, Singapore
e Pediatric Pathology Unit, Department of Pediatrics, Faculty of Medicine, Hacettepe University, Ankara, 06230, Turkey
f Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, MO 63110, United States
g Morgridge Institute for Research, Madison, WI 53715, United States
h Pediatric Hematology Unit, Department of Pediatrics, Faculty of Medicine, Hacettepe University, Ankara, 06230, Turkey
i Research Center of Fanconi Anemia and Other Inherited Bone Marrow Failure Syndromes, Hacettepe University, Ankara, 06230, Turkey
j National Center for Quantitative Biology of Complex Systems, Madison, WI 53562, United States
k Department of Biomolecular Chemistry, University of Wisconsin–Madison, Madison, WI 53562, United States
l Institute of Health Sciences, Koç University, Istanbul, 34010, Turkey
m Yale-NUS College, 12 College Avenue West, Singapore, 138610, Singapore
n Bioinformatics Institute, A<sup>
</sup>STAR, Biopolis, Singapore, 138671, Singapore
o Ankara Child Health and Diseases Hematology Oncology Training and Research Hospital, Ankara, 06110, Turkey
p Pediatric Genetics Unit, Department of Pediatrics, Faculty of Medicine, Hacettepe University, Ankara, 06230, Turkey
q Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, United States
r Intergen Genetic Diagnosis Center, Ankara, 06680, Turkey
s Qatar Genome Program, Qatar Foundation Research, Development and Innovation, Qatar Foundation, Doha, Qatar
t Molecular and Clinical Sciences Institute, St. George’s University of London, Cranmer Terrace, London, UK SW17 0RE, United Kingdom
u Medical Genetics Department, Koç University School of Medicine, Istanbul, 34010, Turkey
v Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, Queen Square, London, UK WC1N 3BG, United Kingdom
w Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, United States
x Texas Children’s Hospital, Houston, TX 77030, United States
y Paris University, Imagine Institute, Paris, 75015, France
z Laboratory of Human Genetics of Infectious Disease, INSERM U1163, Necker Branch, Paris, France
aa Rady Children’s Institute for Genomic Medicine, San Diego, CA 92123, United States
ab Department of Neurosciences, University of California, San Diego, La Jolla, CA 92093, United States
ac St. Giles Laboratory of Human Genetics of Infectious Diseases, The Rockefeller University, Rockefeller Branch, New York, NY 10065, United States
ad Department of Biological Sciences, National University of Singapore, Singapore, 117558, Singapore
ae Department of Chemistry, University of Wisconsin–Madison, Madison, WI 53562, United States
af Farabi Medical Laboratory, Erbil, Iraq
ag Chief Division Pediatric Neurology, Department of Pediatrics, Rafic Hariri University Hospital, Beirut, Lebanon
ah Clinical Genetics Department, National Research Centre, Cairo, 12622, Egypt
ai Corporate Research, The Procter and Gamble Company, Cincinnati, OH 45040, United States
aj Genomic Research, CENTOGENE GmbH, Rostock, 18055, Germany
ak Research Center for Immunodeficiencies, Children’s Medical Center, Tehran University of Medical Sciences, Tehran, 14194, Iran
al Network of Immunity in Infection, Malignancy and Autoimmunity, Universal Scientific Education and Research Network, Tehran, 14197, Iran
am Department of Pediatric Infectious Diseases, Children’s Medical Center, Tehran University of Medical Sciences, Tehran, 14194, Iran
an Laboratoire d’analyses spécialisé en Génétique, Tunis, 1082, Tunisia
ao Division of Genetics, Department of Pediatrics, King Abdullah Specialized Children Hospital, King Abdulaziz Medical City, MNGHA, Riyadh, 14611, Saudi Arabia
ap King Abdullah International Medical Research Center, King Saud bin Abdulaziz University for Health Sciences, MNGHA, Riyadh, 11481, Saudi Arabia
aq Department of Pediatrics, Division of Neurology, University of Gaziantep, School of Medicine, Gaziantep, 27310, Turkey
ar Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX 77030, United States
as Pediatric Immunology-Hematology Unit, Assistance Publique-Hôpitaux de Paris, Necker Hospital for Sick Children, Paris, 75015, France
at Howard Hughes Medical Institute, New York, NY 10065, United States
au Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, MO 63110, United States
av Department of Genetics, Washington University School of Medicine, St. Louis, MO 63110, United States
aw Department of Biochemistry, University of Wisconsin–Madison, Madison, WI 53706, United States
ax Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 117593, Singapore
ay Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 119228, Singapore

Abstract
Human C2orf69 is an evolutionarily conserved gene whose function is unknown. Here, we report eight unrelated families from which 20 children presented with a fatal syndrome consisting of severe autoinflammation and progredient leukoencephalopathy with recurrent seizures; 12 of these subjects, whose DNA was available, segregated homozygous loss-of-function C2orf69 variants. C2ORF69 bears homology to esterase enzymes, and orthologs can be found in most eukaryotic genomes, including that of unicellular phytoplankton. We found that endogenous C2ORF69 (1) is loosely bound to mitochondria, (2) affects mitochondrial membrane potential and oxidative respiration in cultured neurons, and (3) controls the levels of the glycogen branching enzyme 1 (GBE1) consistent with a glycogen-storage-associated mitochondriopathy. We show that CRISPR-Cas9-mediated inactivation of zebrafish C2orf69 results in lethality by 8 months of age due to spontaneous epileptic seizures, which is preceded by persistent brain inflammation. Collectively, our results delineate an autoinflammatory Mendelian disorder of C2orf69 deficiency that disrupts the development/homeostasis of the immune and central nervous systems. © 2021 American Society of Human Genetics

Author Keywords
C2ORF69, mitochondriopathy, inflammation, GBE1, encephalopathy, zebrafish, Elbracht-Işikay syndrome, lipase, glycogen, Mendelian genetics

Funding details
319S062, 825575
HHMI-IRSP55008732, IG19-BG106, NRF-NRFF2017-05
315S192
National Institutes of HealthNIHNMRC/OFYIRG/062/2017, P41 GM108538, R35 GM131795, UW2020
Howard Hughes Medical InstituteHHMI
National Heart, Lung, and Blood InstituteNHLBI
National Human Genome Research InstituteNHGRI
National Institute of Neurological Disorders and StrokeNINDSR35NS105078
International Rett Syndrome FoundationIRSF3701-1
St. Giles Foundation
Procter and GambleP&G
Muscular Dystrophy AssociationMDA512848
Uehara Memorial Foundation
Rockefeller University
Baylor-Hopkins Center for Mendelian GenomicsBHCMG006542
Agency for Science, Technology and ResearchA*STARA?STAR
National Research Foundation SingaporeNRF
Institut National de la Santé et de la Recherche MédicaleInserm

Document Type: Article
Publication Stage: Final
Source: Scopus

“A Real-World, Prospective, Multicenter, Single-Arm Observational Study of Duloxetine in Patients With Major Depressive Disorder or Generalized Anxiety Disorder” (2021) Frontiers in Psychiatry

A Real-World, Prospective, Multicenter, Single-Arm Observational Study of Duloxetine in Patients With Major Depressive Disorder or Generalized Anxiety Disorder
(2021) Frontiers in Psychiatry, 12, art. no. 689143, . 

Szekeres, G.a , Rozsa, S.b c , Dome, P.a d , Barsony, G.e , Gonda, X.a

a Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary
b Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, United States
c Károli Gáspár University of the Reformed Church in Hungary, Budapest, Hungary
d Nyiro Gyula National Institute of Psychiatry and Addictions, Budapest, Hungary
e Research Flow Kft, Budapest, Hungary

Abstract
Background: Suboptimal treatment response during anti-depressive treatment is fairly common with the first antidepressant (AD) choice, followed by switching to another agent in the majority of cases. However, the efficacy of this strategy over continuation of the original agent is less solidly documented in real-life studies. The aim of our present study was to ascertain the effects of switching to duloxetine following inadequate response to prior ADs on general illness severity, pain, and health-related quality of life in a large sample of major depressive disorder (MDD) and generalized anxiety disorder (GAD) patients in a prospective, real-world, multicenter, observational study. Methods: A total of 578 participants with MDD or GAD were enrolled in 58 outpatient sites in an 8-week, single-arm, open-label, flexible-dose trial with duloxetine. Severity of symptoms [with Clinical Global Impression-Severity (CGI-S) and Clinical Global Impression-Improvement (CGI-I)], severity of pain (with a Visual Analog Scale), satisfaction with current treatment, and health-related quality of life [with the three-level version of the EuroQol five-dimensional questionnaire (EQ-5D-3L)] measures were recorded at baseline and at follow-up visits 4 and 8 weeks after initiation of treatment. Data were analyzed using ANOVA and mixed linear models. Results: 565 patients completed the study and comprised the analyzed dataset. Results indicated that severity of illness significantly decreased over the 8 weeks of the study and already at 4 weeks in both patient groups. Overall quality of life and all of its subindicators also significantly improved in both patient groups and so did subjective experience of pain. Satisfaction with current treatment also significantly increased during the study period. Frequency of side effects was low. In both GAD and MDD groups, two patients dropped out of the study due to adverse effects, leading to treatment termination in four cases (0.7%). Conclusions: This 8-week, multicenter, flexible-dosing, single-arm, open-label, observational real-life study in MDD and GAD patients switched to duloxetine after inadequate response or low tolerability to other ADs showed a significant positive effect on all outcome measures, including a significant decrease in illness severity as well as significant overall symptomatic improvement, with good tolerability. © Copyright © 2021 Szekeres, Rozsa, Dome, Barsony and Gonda.

Author Keywords
clinical global impression scale;  duloxetine;  generalized anxiety disorder;  health-related quality of life;  major depressive disorder

Funding details
Magyar Tudományos AkadémiaMTA

Document Type: Article
Publication Stage: Final
Source: Scopus

“Maturation of Heterogeneity in Afferent Synapse Ultrastructure in the Mouse Cochlea” (2021) Frontiers in Synaptic Neuroscience

Maturation of Heterogeneity in Afferent Synapse Ultrastructure in the Mouse Cochlea
(2021) Frontiers in Synaptic Neuroscience, 13, art. no. 678575, . 

Payne, S.A.a , Joens, M.S.b c , Chung, H.a d , Skigen, N.d , Frank, A.d , Gattani, S.d , Vaughn, K.d , Schwed, A.e , Nester, M.d , Bhattacharyya, A.a d , Iyer, G.d , Davis, B.e , Carlquist, J.a d , Patel, H.d , Fitzpatrick, J.A.J.b f g h , Rutherford, M.A.a

a Department of Otolaryngology, Washington University School of Medicine, St. Louis, MO, United States
b Center for Cellular Imaging, Washington University in St. Louis, St. Louis, MO, United States
c TESCAN USA, Inc, Warrendale, PA, United States
d Department of Biology, Washington University in St. Louis, St. Louis, MO, United States
e Graduate Program in Audiology and Communications Sciences, Washington University School of Medicine, St. Louis, MO, United States
f Department of Neuroscience, Washington University School of Medicine, St. Louis, MO, United States
g Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, MO, United States
h Department of Biomedical Engineering, Washington University School of Medicine, St. Louis, MO, United States

Abstract
Auditory nerve fibers (ANFs) innervating the same inner hair cell (IHC) may have identical frequency tuning but different sound response properties. In cat and guinea pig, ANF response properties correlate with afferent synapse morphology and position on the IHC, suggesting a causal structure-function relationship. In mice, this relationship has not been fully characterized. Here we measured the emergence of synaptic morphological heterogeneities during maturation of the C57BL/6J mouse cochlea by comparing postnatal day 17 (p17, 
3 days after hearing onset) with p34, when the mouse cochlea is mature. Using serial block face scanning electron microscopy and three-dimensional reconstruction we measured the size, shape, vesicle content, and position of 70 ribbon synapses from the mid-cochlea. Several features matured over late postnatal development. From p17 to p34, presynaptic densities (PDs) and post-synaptic densities (PSDs) became smaller on average (PDs: 0.75 to 0.33; PSDs: 0.58 to 0.31 μm2) and less round as their short axes shortened predominantly on the modiolar side, from 770 to 360 nm. Membrane-associated synaptic vesicles decreased in number from 53 to 30 per synapse from p17 to p34. Anatomical coupling, measured as PSD to ribbon distance, tightened predominantly on the pillar side. Ribbons became less spherical as long-axes lengthened only on the modiolar side of the IHC, from 372 to 541 nm. A decreasing gradient of synaptic ribbon size along the modiolar-pillar axis was detected only at p34 after aligning synapses of adjacent IHCs to a common reference frame (median volumes in nm3 × 106: modiolar 4.87; pillar 2.38). The number of ribbon-associated synaptic vesicles scaled with ribbon size (range 67 to 346 per synapse at p34), thus acquiring a modiolar-pillar gradient at p34, but overall medians were similar at p17 (120) and p34 (127), like ribbon surface area (0.36 vs. 0.34 μm2). PD and PSD morphologies were tightly correlated to each other at individual synapses, more so at p34 than p17, but not to ribbon morphology. These observations suggest that PDs and PSDs mature according to different cues than ribbons, and that ribbon size may be more influenced by cues from the IHC than the surrounding tissue. © Copyright © 2021 Payne, Joens, Chung, Skigen, Frank, Gattani, Vaughn, Schwed, Nester, Bhattacharyya, Iyer, Davis, Carlquist, Patel, Fitzpatrick and Rutherford.

Author Keywords
developmental maturation;  FIB-SEM;  modiolar;  pillar;  postsynaptic density;  presynaptic density;  ribbon synapse ultrastructure;  synaptic vesicles

Funding details
S10OD021629
CDI-CORE-2015-505
National Institutes of HealthNIH
National Institute on Deafness and Other Communication DisordersNIDCDR01DC014712
Foundation for Barnes-Jewish Hospital
Washington University School of Medicine in St. Louis
Center for Cellular Imaging, Washington UniversityWUCCI

Document Type: Article
Publication Stage: Final
Source: Scopus

“Distinct MicroRNA Profiles in the Perilymph and Serum of Patients With Menière’s Disease” (2021) Frontiers in Neurology

Distinct MicroRNA Profiles in the Perilymph and Serum of Patients With Menière’s Disease
(2021) Frontiers in Neurology, 12, art. no. 646928, . 

Shew, M.a , Wichova, H.b , St. Peter, M.b , Warnecke, A.c , Staecker, H.b

a Department of Otolaryngology Head and Neck Surgery, Washington University School of Medicine in St. Louis, St. Louis, MO, United States
b Department of Otolaryngology Head and Neck Surgery, University of Kansas, School of Medicine, Kansas City, KS, United States
c Department of Otolaryngology Head and Neck Surgery, Hannover Medical School, Hanover, Germany

Abstract
Hypothesis: Menière’s disease microRNA (miRNA) profiles are unique and are reflected in the perilymph and serum of patients. Background: Development of effective biomarkers for Menière’s disease are needed. miRNAs are small RNA sequences that downregulate mRNA translation and play a significant role in a variety of disease states, ultimately making them a promising biomarker. miRNAs can be readily isolated from human inner ear perilymph and serum, and may exhibit disease-specific profiles. Methods: Perilymph sampling was performed in 10 patients undergoing surgery; 5 patients with Meniere’s disease and 5 patients with otosclerosis serving as controls. miRNAs were isolated from the serum of 5 patients with bilateral Menière’s disease and compared to 5 healthy age-matched controls. For evaluation of miRNAs an Agilent miRNA gene chip was used. Analysis of miRNA expression was carried out using Qlucore and Ingenuitey Pathway Analysis software. Promising miRNAs biomarkers were validated using qPCR. Results: In the perilymph of patients with Menière’s disease, we identified 16 differentially expressed miRNAs that are predicted to regulate over 220 different cochlear genes. Six miRNAs are postulated to regulate aquaporin expression and twelve miRNAs are postulated to regulate a variety of inflammatory and autoimmune pathways. When comparing perilymph with serum samples, miRNA-1299 and−1270 were differentially expressed in both the perilymph and serum of Ménière’s patients compared to controls. Further analysis using qPCR confirmed miRNA-1299 is downregulated over 3-fold in Meniere’s disease serum samples compared to controls. Conclusions: Patients with Ménière’s disease exhibit distinct miRNA expression profiles within both the perilymph and serum. The altered perilymph miRNAs identified can be linked to postulated Ménière’s disease pathways and may serve as biomarkers. miRNA-1299 was validated to be downregulated in both the serum and perilymph of Menière’s patients. © Copyright © 2021 Shew, Wichova, St. Peter, Warnecke and Staecker.

Author Keywords
biomarker;  liquid biopsy;  Meniere disease;  microRNA;  perilymph

Funding details
National Cancer InstituteNCIP30 CA168524
National Institute of General Medical SciencesNIGMSP20GM103418
University of KansasKU

Document Type: Article
Publication Stage: Final
Source: Scopus

“Group characterization of impact-induced, in vivo human brain kinematics” (2021) Journal of the Royal Society, Interface

Group characterization of impact-induced, in vivo human brain kinematics
(2021) Journal of the Royal Society, Interface, 18 (179), p. 20210251. 

Gomez, A.D.a , Bayly, P.V.b , Butman, J.A.c , Pham, D.L.d , Prince, J.L.e , Knutsen, A.K.d

a School of Medicine, Department of Neurology, Johns Hopkins University, 200 Carnegie Hall, MD, 600 North Wolfe Street, Baltimore, United States
b Department of Mechanical Engineering and Materials Science, Washington University in St Louis, MI, 1 Brookings Drive, Box 1185, Saint Louis, United States
c Clinical Center, National Institutes of Health, MD, Bethesda, United States
d Center for Neuroscience and Regenerative Medicine, Henry M Jackson Foundation for the Advancement of Military Medicine Inc, MD, Bethesda, United States
e Department of Electrical and Computer Engineering, Johns Hopkins University, MD, Baltimore, United States

Abstract
Brain movement during an impact can elicit a traumatic brain injury, but tissue kinematics vary from person to person and knowledge regarding this variability is limited. This study examines spatio-temporal brain-skull displacement and brain tissue deformation across groups of subjects during a mild impact in vivo. The heads of two groups of participants were imaged while subjected to a mild (less than 350 rad s-2) impact during neck extension (NE, n = 10) and neck rotation (NR, n = 9). A kinematic atlas of displacement and strain fields averaged across all participants was constructed and compared against individual participant data. The atlas-derived mean displacement magnitude was 0.26 ± 0.13 mm for NE and 0.40 ± 0.26 mm for NR, which is comparable to the displacement magnitudes from individual participants. The strain tensor from the atlas displacement field exhibited maximum shear strain (MSS) of 0.011 ± 0.006 for NE and 0.017 ± 0.009 for NR and was lower than the individual MSS averaged across participants. The atlas illustrates common patterns, containing some blurring but visible relationships between anatomy and kinematics. Conversely, the direction of the impact, brain size, and fluid motion appear to underlie kinematic variability. These findings demonstrate the biomechanical roles of key anatomical features and illustrate common features of brain response for model evaluation.

Author Keywords
dynamic magnetic resonance imaging;  finite strain;  head impact;  traumatic brain injury

Document Type: Article
Publication Stage: Final
Source: Scopus

“Biallelic variants in HPDL cause pure and complicated hereditary spastic paraplegia” (2021) Brain

Biallelic variants in HPDL cause pure and complicated hereditary spastic paraplegia
(2021) Brain, 144 (5), pp. 1422-1434. 

Wiessner, M.a , Maroofian, R.b , Ni, M.-Y.c , Pedroni, A.d , Müller, J.S.e , Stucka, R.a , Beetz, C.e , Efthymiou, S.b , Santorelli, F.M.g , Alfares, A.A.h , Zhu, C.i j k , Uhrova Meszarosova, A.l , Alehabib, E.m , Bakhtiari, S.n , Janecke, A.R.o p , Otero, M.G.q , Chen, J.Y.H.r , Peterson, J.T.s , Strom, T.M.t , De Jonghe, P.u v w , Deconinck, T.x , De Ridder, W.u v w , De Winter, J.u v w , Pasquariello, R.g , Ricca, I.g , Alfadhel, M.y , Van De Warrenburg, B.P.z , Portier, R.aa , Bergmann, C.ab ac , Ghasemi Firouzabadi, S.ad , Jin, S.C.ae , Bilguvar, K.af ag , Hamed, S.ah , Abdelhameed, M.ah , Haridy, N.A.b ah , Maqbool, S.ai , Rahman, F.ai , Anwar, N.ai , Carmichael, J.aj , Pagnamenta, A.ak , Wood, N.W.b al , Tran Mau-Them, F.am , Haack, T.an , Di Rocco, M.ao , Ceccherini, I.ap , Iacomino, M.aq , Zara, F.aq ar , Salpietro, V.ar as , Scala, M.ar as , Rusmini, M.ap , Xu, Y.i , Wang, Y.at , Suzuki, Y.au , Koh, K.av , Nan, H.av , Ishiura, H.aw , Tsuji, S.ax , Lambert, L.ay , Schmitt, E.az , Lacaze, E.ba , Küpper, H.bb , Dredge, D.r , Skraban, C.bc bd , Goldstein, A.s bd , Willis, M.J.H.be , Grand, K.bf , Graham, J.M.bf , Lewis, R.A.bg , Millan, F.bh , Duman, Ö.bi , Dündar, N.bj , Uyanik, G.bk bl , Schöls, L.bm bn , Nürnberg, P.bo , Nürnberg, G.bo , Catala Bordes, A.l , Seeman, P.l , Kuchar, M.bp , Darvish, H.bq , Rebelo, A.br , Bouçanova, F.d bs , Medard, J.-J.d bs , Chrast, R.d bs , Auer-Grumbach, M.bt , Alkuraya, F.S.bu , Shamseldin, H.bu , Al Tala, S.bv , Rezazadeh Varaghchi, J.bw , Najafi, M.f bx , Deschner, S.by , Gläser, D.by , Hüttel, W.bz , Kruer, M.C.n , Kamsteeg, E.-J.bx , Takiyama, Y.av , Züchner, S.br , Baets, J.u v w , Synofzik, M.bm bn , Schüle, R.bm bn , Horvath, R.e , Houlden, H.b , Bartesaghi, L.d bs , Lee, H.-J.c , Ampatzis, K.d , Pierson, T.M.f q bg ca , Senderek, J.a , Genomics England Research Consortium, PREPARE networkcb

a Friedrich-Baur-Institute, Department of Neurology, LMU Munich, Munich, Germany
b Department of Neuromuscular Disorders, Institute of Neurology, University College London, London, United Kingdom
c Department of Biochemistry, National Defense Medical Center, Neihu, Taipei, Taiwan
d Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden
e Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom
f Center for the Undiagnosed Patient, Cedars-Sinai Medical Center, Los Angeles, CA, United States
g Molecular Medicine Unit, IRCCS Fondazione Stella Maris, Pisa, Italy
h Department of Pediatrics, College of Medicine, Qassim University, Qassim, Saudi Arabia
i Henan Key Laboratory of Child Brain Injury, Institute of Neuroscience, Third Affliated Hospital of Zhengzhou University, Zhengzhou, China
j Center for Brain Repair and Rehabilitation, Institute of Neuroscience and Physiology, University of Gothenburg, Göteborg, Sweden
k Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden
l DNA Laboratory, Department of Paediatric Neurology, Second Faculty of Medicine, Charles University, University Hospital Motol, Prague, Czech Republic
m Student Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
n Barrow Neurological Institute, Phoenix Children’s Hospital, University of Arizona College of Medicine, Phoenix, United States
o Department of Pediatrics I, Medical University of Innsbruck, Innsbruck, Austria
p Division of Human Genetics, Medical University of Innsbruck, Innsbruck, Austria
q Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA, United States
r Neurology Department, Massachusetts General Hospital, Boston, MA, United States
s Mitochondrial Medicine Frontier Program, Children’s Hospital of Philadelphia, Philadelphia, PA, United States
t Institute of Human Genetics, Technische Universität Mänchen, Munich, Germany
u Translational Neurosciences, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerpen, Belgium
v Laboratory of Neuromuscular Pathology, Institute Born-Bunge, University of Antwerp, Antwerpen, Belgium
w Neuromuscular Reference Centre, Department of Neurology, Antwerp University Hospital, Antwerpen, Belgium
x Center of Medical Genetics, University of Antwerp, Antwerp University Hospital, Antwerpen, Belgium
y Genetics Division, Department of Pediatrics, King Abdullah International Medical Research Center (KAIMRC), King Saud bin Abdulaziz University for Health Sciences, King Abdulaziz Medical City, Ministry of National Guard Health Affairs (MNG-HA), Riyadh, Saudi Arabia
z Department of Neurology, Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Centre, Nijmegen, Netherlands
aa Polikliniek Neurologie Enschede, Medisch Spectrum Twente, Enschede, Netherlands
ab Medizinische Genetik Mainz, Limbach Genetics, Mainz, Germany
ac Department of Medicine, Nephrology, University Hospital Freiburg, Germany
ad Genetics Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran
ae Department of Genetics, Washington University School of Medicine, St. Louis, United States
af Department of Genetics, Yale University School of Medicine, New Haven, CT, United States
ag Yale Center for Genome Analysis, Yale University, New Haven, CT, United States
ah Department of Neurology and Psychiatry, Assiut University Hospital, Assiut, Egypt
ai Development and Behavioural Paediatrics Department, Institute of Child Health, The Children Hospital, Lahore, Pakistan
aj Oxford Regional Clinical Genetics Service, Northampton General Hospital, Northampton, United Kingdom
ak NIHR Oxford BRC, Wellcome Centre for Human Genetics, University of Oxford, Oxford, United Kingdom
al The National Hospital for Neurology and Neurosurgery, London, United Kingdom
am Unité Fonctionnelle 6254 d’Innovation en Diagnostique Génomique des Maladies Rares, Pôle de Biologie, CHU Dijon Bourgogne, Dijon, France
an Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany
ao Rare Diseases Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy
ap Genetics and Genomics of Rare Diseases Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy
aq Medical Genetics Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy
ar Dep. of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, Genoa, Italy
as Pediatric Neurology and Neuromuscular Diseases Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy
at Department of Pediatrics, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China
au Department of Pediatric Neurology, Osaka Women’s and Children’s Hospital, Osaka, Japan
av Department of Neurology, Graduate School of Medical Sciences, University of Yamanashi, Yamanashi, Japan
aw Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
ax Institute of Medical Genomics, International University of Health and Welfare, Chiba, Japan
ay Department of Clinical Genetics, CHRU Nancy, UMR-S INSERM N-GERE 1256, Université de Lorraine, Faculté de Médecine, Nancy, France
az Department of Neuroradiology, CHRU Nancy, Nancy, France
ba Department of Medical Genetics, Le Havre Hospital, Le Havre, France
bb Department of Pediatric Neurology, University Children’s Hospital Tübingen, Tübingen, Germany
bc Roberts Individualized Medical Genetics Center, Division of Human Genetics, Children’s Hospital of Philadelphia, Philadelphia, PA, United States
bd Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States
be Department of Pediatrics, Naval Medical Center San Diego, San Diego, CA, United States
bf Department of Pediatrics, Medical Genetics, Cedars-Sinai Medical Center, Los Angeles, CA, United States
bg Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA, United States
bh GeneDx, Gaithersburg, MD, United States
bi Department of Pediatric Neurology, Akdeniz University Hospital, Antalya, Turkey
bj Department of Pediatric Neurology, Izmir Katip Celebi University, Izmir, Turkey
bk Center for Medical Genetics, Hanusch Hospital, Vienna, Austria
bl Medical School, Sigmund Freud Private University, Vienna, Austria
bm Hertie Institute for Clinical Brain Research (HIH), Center of Neurology, University of Tübingen, Tübingen, Germany
bn German Center for Neurodegenerative Diseases (DZNE), University of Tübingen, Tübingen, Germany
bo Cologne Center for Genomics, Faculty of Medicine, Cologne University Hospital, University of Cologne, Cologne, Germany
bp Department of Paediatric Neurology, Liberec Hospital, Liberec, Czech Republic
bq Neuroscience Research Center, Faculty of Medicine, Golestan University of Medical Sciences, Gorgan, Iran
br Dr. John T. Macdonald Foundation, Department of Human Genetics, John P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, FL, United States
bs Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
bt Department of Orthopaedics and Traumatology, Medical University of Vienna, Vienna, Austria
bu Department of Translational Genomics, Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
bv Department of Pediatrics, Genetic Unit, Armed Forces Hospital, Khamis Mushayt, Saudi Arabia
bw Hasti Genetic Counseling Center of Welfare Organization of Southern Khorasan, Birjand, Iran
bx Department of Human Genetics, Radboud University Medical Center, Nijmegen, Netherlands
by genetikum, Center for Human Genetics, Neu-Ulm, Germany
bz Institut für Pharmazeutische Wissenschaften, Albert-Ludwigs-Universität Freiburg, Freibug, Germany
ca Department of Pediatrics, Cedars-Sinai Medical Center, Los Angeles, CA, United States

Abstract
Human 4-hydroxyphenylpyruvate dioxygenase-like (HPDL) is a putative iron-containing non-heme oxygenase of unknown specificity and biological significance. We report 25 families containing 34 individuals with neurological disease associated with biallelic HPDL variants. Phenotypes ranged from juvenile-onset pure hereditary spastic paraplegia to infantile-onset spasticity and global developmental delays, sometimes complicated by episodes of neurological and respiratory decompensation. Variants included bona fide pathogenic truncating changes, although most were missense substitutions. Functionality of variants could not be determined directly as the enzymatic specificity of HPDL is unknown; however, when HPDL missense substitutions were introduced into 4-hydroxyphenylpyruvate dioxygenase (HPPD, an HPDL orthologue), they impaired the ability of HPPD to convert 4-hydroxyphenylpyruvate into homogentisate. Moreover, three additional sets of experiments provided evidence for a role of HPDL in the nervous system and further supported its link to neurological disease: (i) HPDL was expressed in the nervous system and expression increased during neural differentiation; (ii) knockdown of zebrafish hpdl led to abnormal motor behaviour, replicating aspects of the human disease; and (iii) HPDL localized to mitochondria, consistent with mitochondrial disease that is often associated with neurological manifestations. Our findings suggest that biallelic HPDL variants cause a syndrome varying from juvenile-onset pure hereditary spastic paraplegia to infantile-onset spastic tetraplegia associated with global developmental delays. © 2021 The Author(s).

Author Keywords
autosomal recessive;  hereditary spastic paraplegia;  HPDL;  HSP;  mitochondrial disorder

Funding details
01GM1511
MAB-108-070
01GM1607, 01GM1905
National Institute of Neurological Disorders and StrokeNINDSR01NS072248
Japan Agency for Medical Research and DevelopmentAMED19ek0109279h0003
Wellcome TrustWTWT093205, WT104033AIA
Newton FundMR/ N027302/1
Ministerio de Sanidad, Consumo y Bienestar SocialMISAN441409627, EJP RD COFUND-EJP N 825575
Medical Research CouncilMRC109915/Z/15/Z, MR/N025431/1
Deutsche ForschungsgemeinschaftDFG
Ministry of Education, Culture, Sports, Science and TechnologyMonbusho
ZonMw
Bundesministerium für Bildung und ForschungBMBF
Fonds Wetenschappelijk OnderzoekFWO1805016N
Ministero della SaluteRC5X1000, RF-2016- 02361610
Ministerstvo Zdravotnictví Ceské RepublikyMZCRAZV NU20-04- 00279, DRO 00064203
Ministry of Health, Labour and WelfareMHLWJP18K07495
VetenskapsrådetVR2018-02667, 717791
Ministry of Science and Technology, TaiwanMOST107-2320-B-016-014
Horizon 2020779257
Major Science and Technology Project of Hainan Province171100310200
Research Committee for Ataxic Disease

Document Type: Article
Publication Stage: Final
Source: Scopus

“Phenotypic expansion of CACNA1C-associated disorders to include isolated neurological manifestations” (2021) Genetics in Medicine

Phenotypic expansion of CACNA1C-associated disorders to include isolated neurological manifestations
(2021) Genetics in Medicine, . 

Rodan, L.H.a b , Spillmann, R.C.c , Kurata, H.T.d , Lamothe, S.M.d , Maghera, J.d , Jamra, R.A.e , Alkelai, A.f , Antonarakis, S.E.g , Atallah, I.h , Bar-Yosef, O.i j , Bilan, F.k , Bjorgo, K.l , Blanc, X.g , Van Bogaert, P.m , Bolkier, Y.j n , Burrage, L.C.o , Christ, B.U.p , Granadillo, J.L.q , Dickson, P.q , Donald, K.A.p , Dubourg, C.r s , Eliyahu, A.j t u , Emrick, L.o , Engleman, K.v , Gonfiantini, M.V.w , Good, J.-M.x , Kalser, J.x , Kloeckner, C.e , Lachmeijer, G.y , Macchiaiolo, M.w , Nicita, F.z , Odent, S.aa , O’Heir, E.a ab , Ortiz-Gonzalez, X.ac , Pacio-Miguez, M.ad , Palomares-Bralo, M.ad , Pena, L.ae af , Platzer, K.e , Quinodoz, M.ag ah , Ranza, E.g , Rosenfeld, J.A.o , Roulet-Perez, E.x , Santani, A.ai aj , Santos-Simarro, F.ad , Pode-Shakked, B.j ak , Skraban, C.aj al , Slaugh, R.q , Superti-Furga, A.x , Thiffault, I.v , van Jaabrsveld, R.H.y , Vincent, M.am , Wang, H.-G.an , Zacher, P.ao , Alejandro, M.E.at , Azamian, M.S.at , Bacino, C.A.at , Balasubramanyam, A.at , Burrage, L.C.at , Chao, H.-T.at , Clark, G.D.at , Craigen, W.J.at , Dai, H.at , Dhar, S.U.at , Emrick, L.T.at , Goldman, A.M.at , Hanchard, N.A.at , Jamal, F.at , Karaviti, L.at , Lalani, S.R.at , Lee, B.H.at , Lewis, R.A.at , Marom, R.at , Moretti, P.M.at , Murdock, D.R.at , Nicholas, S.K.at , Orengo, J.P.at , Posey, J.E.at , Potocki, L.at , Rosenfeld, J.A.at , Samson, S.L.at , Scott, D.A.at , Tran, A.A.at , Vogel, T.P.at , Wangler, M.F.au , Yamamoto, S.au , Eng, C.M.av , Liu, P.av , Ward, P.A.av , Behrens, E.aw , Deardorff, M.aw , Falk, M.aw , Hassey, K.aw , Sullivan, K.aw , Vanderver, A.aw , Goldstein, D.B.ax , Cope, H.ay , McConkie-Rosell, A.ay , Schoch, K.ay , Shashi, V.ay , Smith, E.C.ay , Spillmann, R.C.ay , Sullivan, J.A.ay , Tan, Q.K.-G.ay , Walley, N.M.ay , Agrawal, P.B.az , Beggs, A.H.az , Berry, G.T.az , Briere, L.C.az , Cobban, L.A.az , Coggins, M.az , Cooper, C.M.az , Fieg, E.L.az , High, F.az , Holm, I.A.az , Korrick, S.az , Krier, J.B.az , Lincoln, S.A.az , Loscalzo, J.az , Maas, R.L.az , MacRae, C.A.az , Pallais, J.C.az , Rao, D.A.az , Rodan, L.H.az , Silverman, E.K.az , Stoler, J.M.az , Sweetser, D.A.az , Walker, M.az , Walsh, C.A.az , Esteves, C.ba , Kelley, E.G.ba , Kohane, I.S.ba , LeBlanc, K.ba , McCray, A.T.ba , Nagy, A.ba , Dasari, S.bb , Lanpher, B.C.bb , Lanza, I.R.bb , Morava, E.bb , Oglesbee, D.bb , Bademci, G.bc , Barbouth, D.bc , Bivona, S.bc , Carrasquillo, O.bc , Chang, T.C.P.bc , Forghani, I.bc , Grajewski, A.bc , Isasi, R.bc , Lam, B.bc , Levitt, R.bc , Liu, X.Z.bc , McCauley, J.bc , Sacco, R.bc , Saporta, M.bc , Schaechter, J.bc , Tekin, M.bc , Telischi, F.bc , Thorson, W.bc , Zuchner, S.bc , Colley, H.A.bd , Dayal, J.G.bd , Eckstein, D.J.bd , Findley, L.C.bd , Krasnewich, D.M.bd , Mamounas, L.A.bd , Manolio, T.A.bd , Mulvihill, J.J.bd , LaMoure, G.L.bd , Goldrich, M.P.bd , Urv, T.K.bd , Doss, A.L.bd , Acosta, M.T.be , Bonnenmann, C.be , D’Souza, P.be , Draper, D.D.be , Ferreira, C.be , Godfrey, R.A.be , Groden, C.A.be , Macnamara, E.F.be , Maduro, V.V.be , Markello, T.C.be , Nath, A.be , Novacic, D.be , Pusey, B.N.be , Toro, C.be , Wahl, C.E.be , Baker, E.bf , Burke, E.A.bg , Adams, D.R.bg , Gahl, W.A.bg , Malicdan, M.C.V.bg , Tifft, C.J.bg , Wolfe, L.A.bg , Yang, J.bg , Power, B.bg , Gochuico, B.bg , Huryn, L.bg , Latham, L.bg , Davis, J.bg , Mosbrook-Davis, D.bg , Rossignol, F.bg , Ben Solomonbg , MacDowall, J.bg , Thurm, A.bg , Zein, W.bg , Yousef, M.bg , Adam, M.bh , Amendola, L.bh , Bamshad, M.bh , Beck, A.bh , Bennett, J.bh , Berg-Rood, B.bh , Blue, E.bh , Boyd, B.bh , Byers, P.bh , Chanprasert, S.bh , Cunningham, M.bh , Dipple, K.bh , Doherty, D.bh , Earl, D.bh , Glass, I.bh , Golden-Grant, K.bh , Hahn, S.bh , Hing, A.bh , Hisama, F.M.bh , Horike-Pyne, M.bh , Jarvik, G.P.bh , Jarvik, J.bh , Jayadev, S.bh , Lam, C.bh , Maravilla, K.bh , Mefford, H.bh , Merritt, J.L.bh , Mirzaa, G.bh , Nickerson, D.bh , Raskind, W.bh , Rosenwasser, N.bh , Scott, C.R.bh , Sun, A.bh , Sybert, V.bh , Wallace, S.bh , Wener, M.bh , Wenger, T.bh , Ashley, E.A.bi , Bejerano, G.bi , Bernstein, J.A.bi , Bonner, D.bi , Coakley, T.R.bi , Fernandez, L.bi , Fisher, P.G.bi , Fresard, L.bi , Hom, J.bi , Huang, Y.bi , Kohler, J.N.bi , Kravets, E.bi , Majcherska, M.M.bi , Martin, B.A.bi , Marwaha, S.bi , McCormack, C.E.bi , Raja, A.N.bi , Reuter, C.M.bi , Ruzhnikov, M.bi , Sampson, J.B.bi , Smith, K.S.bi , Sutton, S.bi , Tabor, H.K.bi , Tucker, B.M.bi , Wheeler, M.T.bi , Zastrow, D.B.bi , Zhao, C.bi , Byrd, W.E.bj , Crouse, A.B.bj , Might, M.bj , Nakano-Okuno, M.bj , Whitlock, J.bj , Brown, G.bk , Butte, M.J.bk , Dell’Angelica, E.C.bk , Dorrani, N.bk , Douine, E.D.bk , Fogel, B.L.bk , Gutierrez, I.bk , Huang, A.bk , Krakow, D.bk , Lee, H.bk , Loo, S.K.bk , Mak, B.C.bk , Martin, M.G.bk , Martínez-Agosto, J.A.bk , McGee, E.bk , Nelson, S.F.bk , Nieves-Rodriguez, S.bk , Palmer, C.G.S.bk , Papp, J.C.bk , Parker, N.H.bk , Renteria, G.bk , Signer, R.H.bk , Sinsheimer, J.S.bk , Wan, J.bk , Wang, L.-K.bk , Perry, K.W.bk , Woods, J.D.bk , Alvey, J.bl , Andrews, A.bl , Bale, J.bl , Bohnsack, J.bl , Botto, L.bl , Carey, J.bl , Pace, L.bl , Longo, N.bl , Marth, G.bl , Moretti, P.bl , Quinlan, A.bl , Velinder, M.bl , Viskochil, D.bl , Bayrak-Toydemir, P.bm , Mao, R.bm , Westerfield, M.bn , Bican, A.bo , Brokamp, E.bo , Duncan, L.bo , Hamid, R.bo , Kennedy, J.bo , Kozuira, M.bo , Newman, J.H.bo , PhillipsIII, J.A.bo , Rives, L.bo , Robertson, A.K.bo , Solem, E.bo , Cogan, J.D.bo , Cole, F.S.bp , Hayes, N.bp , Kiley, D.bp , Sisco, K.bp , Wambach, J.bp , Wegner, D.bp , Baldridge, D.bp , Pak, S.bp , Schedl, T.bp , Shin, J.bp , Solnica-Krezel, L.bp , Rush, E.ap aq ar , Pitt, G.an , Au, P.Y.B.as , Shashi, V.c , Undiagnosed Diseases Networkbq

a Division of Genetics and Genomics, Department of Pediatrics, Boston Children’s Hospital, Boston, MA, United States
b Department of Neurology, Boston Children’s Hospital, Boston, MA, United States
c Division of Medical Genetics, Department of Pediatrics, Duke Health, Durham, NC, United States
d Department of Pharmacology, Alberta Diabetes Institute, University of Alberta, Edmonton, AB, Canada
e Institute of Human Genetics, University of Leipzig Medical Center, Leipzig, Germany
f Institute for Genomic Medicine, Columbia University Medical Center, New York, NY, United States
g Medigenome, Swiss Institute of Genomic Medicine, Geneva, Switzerland
h Division of Genetic Medicine, Lausanne University Hospital, Lausanne, Switzerland
i Pediatric Neurology Unit, Edmond and Lily Safra Children’s Hospital, Sheba Medical Center, Tel-Hahsomer, Israel
j Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
k CHU de Poitiers, Service de Génétique, EA3808 NEUVACOD, Poitiers, France
l Department of Medical Genetics, Oslo University Hospital, Oslo, Norway
m CHU d’Angers, Service de Pédiatrie, EA3808 NEUVACOD, Angers, France
n Pediatric Cardiology Unit, Edmond and Lily Safra Children’s Hospital, Sheba Medical Center, Tel-Hahsomer, Israel
o Department of Molecular & Human Genetics, Baylor College of Medicine, Houston, TX, United States
p Department of Paediatrics and Child Health, Red Cross War Memorial Children’s Hospital, University of Cape Town, Cape Town, SA, South Africa
q Division of Genetics and Genomic Medicine, Department of Pediatrics, Washington University School of Medicine in St. Louis, St. Louis, MO, United States
r Service de Génétique Moléculaire et Génomique, CHU, Rennes, France
s University of Rennes, CNRS, IGDR, UMR 6290, Rennes, France
t The Danek Gertner Insitute of Human Genetics, Sheba Medical Center, Tel-Hahsomer, Israel
u Edmond and Lily Safra Children’s Hospital, Sheba Medical Center, Tel-Hahsomer, Israel
v Center for Pediatric Genomic Medicine, Children’s Mercy Hospital, Kansas City, MO, United States
w Rare Diseases and Medical Genetic Unit, IRCCS Bambino Gesù Children’s Hospital, Rome, Italy
x Pediatric Neurology, Lausanne University Hospital, Lausanne, Switzerland
y Department of Genetics, University Medical Center Utrecht, Utrecht, Netherlands
z Unit of Neuromuscular and Neurodegenerative Diseases, Department of Neurosciences and Neurorehabilitation, IRCCS Bambino Gesù Children’s Hospital, Rome, Italy
aa Service de Génétique Clinique, Centre de référence “Maladies Rares” Anomalies du développement CLAD-Ouest, Hôpital SUD, Échirolles, France
ab Center for Mendelian Genomics and Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, United States
ac Division of Neurology, Children’s Hospital of Philadelphia, Philadelphia, PA, United States
ad Instituto de Genética Médica y Molecular (INGEMM), Hospital Universitario La Paz, IdiPAZ, CIBERER, ISCIII, Madrid, Spain
ae Cincinnati Children’s Hospital and Medical Center Cincinnati, Cincinnati, OH, United States
af University of Cincinnati College of Medicine Cincinnati, Cincinnati, OH, United States
ag Institute of Molecular and Clinical Ophthalmology Basel (IOB), Basel, Switzerland
ah Department of Ophthalmology, University of Basel, Basel, Switzerland
ai Division of Genomic Diagnostics, Children’s Hospital of Philadelphia, Philadelphia, PA, United States
aj Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States
ak Institute of Rare Diseases, Edmond and Lily Safra Children’s Hospital, Sheba Medical Center, Tel-Hahsomer, Israel
al Division of Human Genetics, Children’s Hospital of Philadelphia, Philadelphia, PA, United States
am Service de Génétique Médicale, CHU Nantes, France; Inserm, CNRS, Univ Nantes, l’institut du thorax, Nantes, France
an Cardiovascular Research Institute, Weill Cornell Medicine, New York, NY, United States
ao The Saxon Epilepsy Center Kleinwachau, Radeberg, Germany
ap The Children’s Mercy Hospital, Kansas City, MO, United States
aq Department of Pediatrics University of Missouri—Kansas City, Kansas City, MO, United States
ar Department of Internal Medicine, University of Kansas Medical Center, Kansas City, MO, United States
as Alberta Children’s Hospital Research Institute, Department of Genetics, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
at BCM Clinical, Houston, TX, United States
au BCM MOSC, Houston, TX, United States
av BCM Sequencing, Houston, TX, United States
aw CHOP, Philadelphia, PA, United States
ax Columbia University, New York, NY, United States
ay Duke University, Durham, NC, United States
az Harvard University, Boston, MA, United States
ba Harvard CC, Boston, MA, United States
bb Mayo Clinic, Rochester, MN, United States
bc Miami, Miami, FL, United States
bd NIH, Bethesda, MD, United States
be NIH UDP, Bethesda, MD, United States
bf NIH UDP, DRM, Bethesda, MD, United States
bg NIH UDP, NHGRI, Bethesda, MD, United States
bh PNW, Seattle, WA, United States
bi Stanford, Stanford, CA, United States
bj UAB CC, Birmingham, AL, United States
bk UCLA, Los Angeles, CA, United States
bl University of Utah, Salt Lake City, UT, United States
bm University of Utah/ARUP, Salt Lake City, UT, United States
bn UO MOSC, Eugene, OR, United States
bo Vanderbilt, Nashville, TN, United States
bp Washington University Clinical, St. Louis, MO, United States

Abstract
Purpose: CACNA1C encodes the alpha-1-subunit of a voltage-dependent L-type calcium channel expressed in human heart and brain. Heterozygous variants in CACNA1C have previously been reported in association with Timothy syndrome and long QT syndrome. Several case reports have suggested that CACNA1C variation may also be associated with a primarily neurological phenotype. Methods: We describe 25 individuals from 22 families with heterozygous variants in CACNA1C, who present with predominantly neurological manifestations. Results: Fourteen individuals have de novo, nontruncating variants and present variably with developmental delays, intellectual disability, autism, hypotonia, ataxia, and epilepsy. Functional studies of a subgroup of missense variants via patch clamp experiments demonstrated differential effects on channel function in vitro, including loss of function (p.Leu1408Val), neutral effect (p.Leu614Arg), and gain of function (p.Leu657Phe, p.Leu614Pro). The remaining 11 individuals from eight families have truncating variants in CACNA1C. The majority of these individuals have expressive language deficits, and half have autism. Conclusion: We expand the phenotype associated with CACNA1C variants to include neurodevelopmental abnormalities and epilepsy, in the absence of classic features of Timothy syndrome or long QT syndrome. © 2021, The Author(s), under exclusive licence to the American College of Medical Genetics and Genomics.

Funding details
B2017/BMD-3721
U01HG007709
National Institutes of HealthNIH
National Human Genome Research InstituteNHGRIR01 HG009141, UM1 HG008900
Duke University1RO1HD090132-01A1
Cornell UniversityCU
Baylor College of MedicineU01HG007672
Rare Disease FoundationRDF
Canadian Institutes of Health ResearchCIHRMOP-97988
University of AlbertaUofA

Document Type: Article
Publication Stage: Article in Press
Source: Scopus

“A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease” (2021) Nature Medicine

A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease
(2021) Nature Medicine, . 

Salloway, S.a , Farlow, M.b , McDade, E.c , Clifford, D.B.c , Wang, G.c , Llibre-Guerra, J.J.c , Hitchcock, J.M.d , Mills, S.L.c , Santacruz, A.M.c , Aschenbrenner, A.J.c , Hassenstab, J.c , Benzinger, T.L.S.c , Gordon, B.A.c , Fagan, A.M.c , Coalier, K.A.c , Cruchaga, C.c , Goate, A.A.e , Perrin, R.J.c , Xiong, C.c , Li, Y.c , Morris, J.C.c , Snider, B.J.c , Mummery, C.f , Surti, G.M.a , Hannequin, D.g , Wallon, D.g , Berman, S.B.h , Lah, J.J.i , Jimenez-Velazquez, I.Z.j , Roberson, E.D.k , van Dyck, C.H.l , Honig, L.S.m , Sánchez-Valle, R.n , Brooks, W.S.o , Gauthier, S.p , Galasko, D.R.q , Masters, C.L.r , Brosch, J.R.b , Hsiung, G.-Y.R.s , Jayadev, S.t , Formaglio, M.u , Masellis, M.v , Clarnette, R.w , Pariente, J.x , Dubois, B.y , Pasquier, F.z , Jack, C.R., Jr.aa , Koeppe, R.ab , Snyder, P.J.ac , Aisen, P.S.ad , Thomas, R.G.q , Berry, S.M.ae , Wendelberger, B.A.ae , Andersen, S.W.af , Holdridge, K.C.af , Mintun, M.A.af , Yaari, R.af , Sims, J.R.af , Baudler, M.ag , Delmar, P.ag , Doody, R.S.ag , Fontoura, P.ag , Giacobino, C.ag , Kerchner, G.A.ag , Bateman, R.J.c , Formaglio, M.u , Mills, S.L.c , Pariente, J.x , van Dyck, C.H.l , the Dominantly Inherited Alzheimer Network-Trials Unitah

a Warren Alpert Medical School of Brown University, Providence, RI, United States
b Indiana University School of Medicine, Indianapolis, IN, United States
c Washington University School of Medicine, St. Louis, MO, United States
d Hitchcock Regulatory Consulting, Inc, Fishers, IN, United States
e Icahn School of Medicine at Mount Sinai, New York, NY, United States
f University College London, London, United Kingdom
g Centre Hospitalier Universitaire de Rouen, Rouen, France
h University of Pittsburgh Medical Center, Pittsburgh, PA, United States
i Emory University Medical Center, Atlanta, GA, United States
j University of Puerto Rico School of Medicine, San Juan, Puerto Rico
k University of Alabama at Birmingham School of Medicine, Birmingham, AL, United States
l Yale University School of Medicine, New Haven, CT, United States
m Columbia University Medical Center, New York, NY, United States
n Hospital Clínic i Provincial de Barcelona, August Pi i Sunyer Biomedical Research Institute-Universitat de Barcelona, Barcelona, Spain
o Neuroscience Research Australia, University of New South Wales Medicine, Randwick, NSW, Australia
p McGill Center for Studies in Aging, McGill University, Montreal, QC, Canada
q University of California San Diego, San Diego, CA, United States
r University of Melbourne, Melbourne, VIC, Australia
s University of British Columbia, Vancouver, BC, Canada
t University of Washington School of Medicine, Seattle, WA, United States
u Hospices Civils de Lyon, Lyons, France
v Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
w Australian Alzheimer’s Research Foundation, University of Western Australia, Perth, WA, Australia
x Centre Hospitalier Universitaire de Toulouse, Toulouse, France
y Neurological Institute, Salpetriere University Hospital, Paris, France
z Centre Hospitalier Régional Universitaire de Lille, Lille, France
aa Mayo Clinic, Rochester, MN, United States
ab University of Michigan, Ann Arbor, MI, United States
ac University of Rhode Island, Kingston, RI, United States
ad Keck School of Medicine, University of Southern California, San Diego, CA, United States
ae Berry Consultants, LLC, Austin, TX, United States
af Eli Lilly and Company, Indianapolis, IN, United States
ag F. Hoffmann-La Roche Ltd, Basel, Switzerland

Abstract
Dominantly inherited Alzheimer’s disease (DIAD) causes predictable biological changes decades before the onset of clinical symptoms, enabling testing of interventions in the asymptomatic and symptomatic stages to delay or slow disease progression. We conducted a randomized, placebo-controlled, multi-arm trial of gantenerumab or solanezumab in participants with DIAD across asymptomatic and symptomatic disease stages. Mutation carriers were assigned 3:1 to either drug or placebo and received treatment for 4–7 years. The primary outcome was a cognitive end point; secondary outcomes included clinical, cognitive, imaging and fluid biomarker measures. Fifty-two participants carrying a mutation were assigned to receive gantenerumab, 52 solanezumab and 40 placebo. Both drugs engaged their Aβ targets but neither demonstrated a beneficial effect on cognitive measures compared to controls. The solanezumab-treated group showed a greater cognitive decline on some measures and did not show benefits on downstream biomarkers. Gantenerumab significantly reduced amyloid plaques, cerebrospinal fluid total tau, and phospho-tau181 and attenuated increases of neurofilament light chain. Amyloid-related imaging abnormalities edema was observed in 19.2% (3 out of 11 were mildly symptomatic) of the gantenerumab group, 2.5% of the placebo group and 0% of the solanezumab group. Gantenerumab and solanezumab did not slow cognitive decline in symptomatic DIAD. The asymptomatic groups showed no cognitive decline; symptomatic participants had declined before reaching the target doses. © 2021, The Author(s), under exclusive licence to Springer Nature America, Inc.

Funding details
National Institutes of HealthNIHU01AG042791S1
Foundation for the National Institutes of HealthFNIHR01AG046179, R01AG053267S1
National Institute of Mental HealthNIMH
National Institute on AgingNIA
National Institute of Allergy and Infectious DiseasesNIAID
National Institute of Neurological Disorders and StrokeNINDS
Mayo Clinic
Alzheimer’s AssociationAA
Eli Lilly and Company
Roche
Biogen
National Center for Advancing Translational SciencesNCATS
AbbVie
F. Hoffmann-La Roche
Janssen Pharmaceuticals
Japan Agency for Medical Research and DevelopmentAMED
Avid RadiopharmaceuticalsP01AG003991, P01AG026276, P30 AG066444, U19 AG024904, U19 AG032438
GHR FoundationGHR
Canadian Institutes of Health ResearchCIHR
Alzheimer Society
Korea Health Industry Development InstituteKHIDI
Eisai
Deutsches Zentrum für Neurodegenerative ErkrankungenDZNE

Document Type: Article
Publication Stage: Article in Press
Source: Scopus

“A propensity-matched comparison of long-term disability worsening in patients with multiple sclerosis treated with dimethyl fumarate or fingolimod” (2021) Therapeutic Advances in Neurological Disorders

A propensity-matched comparison of long-term disability worsening in patients with multiple sclerosis treated with dimethyl fumarate or fingolimod
(2021) Therapeutic Advances in Neurological Disorders, 14, . 

Salter, A.a , Lancia, S.a , Cutter, G.b , Marrie, R.A.c , Mendoza, J.P.d , Lewin, J.B.e , Fox Mellen, R.J.f

a Division of Biostatistics, Washington University School in St. Louis, School of Medicine, St. Louis, MO, United States
b Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, United States
c Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada
d Biogen, Cambridge, MA, United States
e Biogen, 225 Binney, St. Cambridge, MA 02142, United States
f Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH, United States

Abstract
Background: Although the aggregate of data among patients with multiple sclerosis (MS) have shown similar efficacy between dimethyl fumarate (DMF) and fingolimod (FTY), most studies have not assessed long-term worsening of disability. We compared long-term disability worsening over 5 years, as assessed by the Patient-Determined Disease Steps (PDDS), among participants with MS treated with DMF or FTY. Methods: We identified individuals in the North American Research Committee on Multiple Sclerosis (NARCOMS) registry who had relapsing-remitting MS (RRMS), residing in the United States (Spring 2011 to Spring 2018), who initiated treatment with DMF (n = 689) or FTY (n = 565) and had 
1 year follow-up on index treatment. Participants receiving DMF who were previously treated with FTY and those on FTY previously treated with DMF were excluded. Propensity score matching at baseline was used to match FTY-treated to DMF-treated participants. Time to 6-month confirmed disability worsening (1-point increase on PDDS, sustained for 6 months) was estimated using Cox regression. A sensitivity analysis was conducted to account for differences in the duration of index exposure between DMF and FTY groups. Results: After propensity score matching, 468 DMF-treated participants were matched with 468 FTY-treated participants. Median treatment duration was 3.0 years for DMF and 4.0 years for FTY. At 5 years, 68.3% [95% confidence interval (CI): 62.4–73.5] of DMF-treated participants and 63.3% (95% CI: 59.6–70.1) treated with FTY were free from 6-month confirmed PDDS worsening [hazard ratio (HR) 1.01 (95% CI: 0.79–1.28); p = 0.95]. Results were similar in the sensitivity analysis: 70.5% (95% CI: 61.8–77.6) of DMF-treated participants and 72.7% (95% CI: 65.4–78.6) of FTY-treated participants were free from 6-month confirmed PDDS worsening [HR: 1.04 (95% CI: 0.71–1.51); p = 0.84]. Conclusions: In participants with MS from the NARCOMS registry, there was no significant difference in confirmed disability (PDDS) worsening over 5 years between those treated with DMF versus FTY. © The Author(s), 2021.

Author Keywords
comparative effectiveness;  dimethyl fumarate;  disability worsening;  fingolimod;  relapsing-remitting multiple sclerosis

Funding details
BiogenTXu000743629/1996-04-04

Document Type: Article
Publication Stage: Final
Source: Scopus

“Potential causal effect of posttraumatic stress disorder on alcohol use disorder and alcohol consumption in individuals of European descent: A Mendelian Randomization Study” (2021) Alcoholism: Clinical and Experimental Research

Potential causal effect of posttraumatic stress disorder on alcohol use disorder and alcohol consumption in individuals of European descent: A Mendelian Randomization Study
(2021) Alcoholism: Clinical and Experimental Research, . 

Bountress, K.E.a , Wendt, F.b , Bustamante, D.a , Agrawal, A.c , Webb, B.a , Gillespie, N.a , Edenberg, H.d , Sheerin, C.a , Johnson, E.c , Polimanti, R.b , Amstadter, A.a , The Psychiatric Genomics Consortium Posttraumatic Stress Disorder Working Groupe

a Virginia Institute for Psychiatric and Behavioral Genetics, Virginia Commonwealth University, Richmond, VA, United States
b Department of Psychiatry, Yale University, New Haven, CT, United States
c Department of Psychiatry, Washington University in St. Louis, St. Louis, MO, United States
d Departments of Biochemistry and Molecular Biology and Medical and Molecular Genetics, Indiana University, Bloomington, IN, United States

Abstract
Background: Posttraumatic stress disorder (PTSD) often co-occurs with alcohol consumption (AC) and alcohol use disorder (AUD). However, it is unknown whether the same etiologic influences that underlie PTSD co-occurring with AUD are those that underlie PTSD and AC individually. Methods: This study used large-scale genome-wide association study (GWAS) data to test whether PTSD and drinks per week [DPW]/AUD are causally related to one another, and, if so, whether PTSD precedes DPW/AUD and/or vice versa. We used Mendelian Randomization methods to analyze European ancestry GWAS summary statistics from the Psychiatric Genomics Consortium (PGC; PTSD), GWAS &amp; Sequencing Consortium of Alcohol and Nicotine Use (GSCAN; DPW), and the Million Veteran Program (MVP; AUD). Results: PTSD exerted a potentially causal effect on AUD (β = 0.039, SE = 0.014, p = 0.005), but not on DPW (β = 0.002, SE = 0.003, p = 0.414). Additionally, neither DPW (β = 0.019, SE = 0.041, p = 0.637) nor AUD (β = 8.87 × 10−4, SE = 0.001, p = 0.441) exerted a causal effect on PTSD. Conclusions: These findings are consistent with the self-medication model, in which individuals misuse alcohol to cope with aversive trauma-related symptoms. These findings extend latent analysis and molecular findings of shared and correlated risk between PTSD and alcohol phenotypes. Given the health behaviors associated with these phenotypes, these findings are important in that they suggest groups to prioritize for prevention efforts. Further, they provide a rationale for future preclinical and clinical studies examining the biological mechanisms by which PTSD may impact AUD. © 2021 by the Research Society on Alcoholism

Author Keywords
alcohol consumption;  alcohol use disorder;  mendelian randomization;  posttraumatic stress disorder

Funding details
R01MH106595
National Institute of Mental HealthNIMHMH109532
National Institute on Drug AbuseNIDA
National Institute on Alcohol Abuse and AlcoholismNIAAA1K01AA025692
01A1, 1K01AA02805801, F32MH122058, R21 DA047527
Vrije Universiteit AmsterdamVU
Nederlandse Organisatie voor Wetenschappelijk OnderzoekNWO480
05003

Document Type: Article
Publication Stage: Article in Press
Source: Scopus

“Variability in Responding to Joint Attention Cues in the First Year is Associated With Autism Outcome” (2021) Journal of the American Academy of Child and Adolescent Psychiatry

Variability in Responding to Joint Attention Cues in the First Year is Associated With Autism Outcome
(2021) Journal of the American Academy of Child and Adolescent Psychiatry, . 

Stallworthy, I.C.a , Lasch, C.a , Berry, D.a , Wolff, J.J.a , Pruett, J.R., Jr.b , Marrus, N.b , Swanson, M.R.c , Botteron, K.N.b , Dager, S.R.d , Estes, A.M.d , Hazlett, H.C.e , Schultz, R.T.f , Zwaigenbaum, L.g , Piven, J.e , Elison, J.T.a , IBIS Networkh

a University of Minnesota, Minneapolis, United States
b Washington University School of Medicine, St. Louis, MO, United States
c University of Texas, Dallas
d University of Washington, Seattle, United States
e University of North Carolina, Chapel Hill, United States
f Children’s Hospital of PhiladelphiaPA, United States
g University of Alberta, Edmonton, Canada

Abstract
Objective: With development, infants become increasingly responsive to the many attention-sharing cues of adults; however, little work has examined how this ability emerges in typical development or in the context of early autism spectrum disorder (ASD). This study characterized variation in the type of cue needed to elicit a response to joint attention (RJA) using the Dimensional Joint Attention Assessment (DJAA) during naturalistic play. Method: We measured the average redundancy of cue type required for infants to follow RJA bids from an experimenter, as well as their response consistency, in 268 infants at high (HR, n = 68) and low (LR, N = 200) familial risk for ASD. Infants were assessed between 8 and 18 months of age and followed up with developmental and clinical assessments at 24 or 36 months. Our sample consisted of LR infants, as well as HR infants who did (HR-ASD) and did not (HR-neg) develop ASD at 24 months. Results: We found that HR and LR infants developed abilities to respond to less redundant (more sophisticated) RJA cues at different rates, and that HR-ASD infants displayed delayed abilities, identifiable as early as 9 months, compared to both HR-neg and LR infants. Interestingly, results suggest that HR-neg infants may exhibit a propensity to respond to less redundant (more sophisticated) RJA cues relative to both HR-ASD and LR infants. Conclusions: Using an approach to characterize variable performance of RJA cue-reading abilities, findings from this study enhance our understanding of both typical and ASD-related proficiencies and deficits in RJA development. © 2021 American Academy of Child and Adolescent Psychiatry

Author Keywords
autism spectrum disorder;  infant siblings;  joint attention;  non-verbal communication;  response to joint attention

Funding details
National Science FoundationNSF00074041, R01 MH104324
National Institutes of HealthNIHR01 HD055741
National Institute of Mental HealthNIMH
National Institute on Drug AbuseNIDA
National Institute of Neurological Disorders and StrokeNINDS
National Institute of Environmental Health SciencesNIEHS
Autism SpeaksAS6020
Bill and Melinda Gates FoundationBMGF
Simons FoundationSF140209, HD079124
Children’s Hospital of PhiladelphiaCHOPHD083091
University of North CarolinaUNC
University of MinnesotaUMN
University of Utah
University of North Carolina WilmingtonUNCWHD087011
University of WashingtonUWHD86984
McDonnell Center for Systems Neuroscience
Eunice Kennedy Shriver National Institute of Child Health and Human DevelopmentNICHD
University of AlbertaUofA

Document Type: Article
Publication Stage: Article in Press
Source: Scopus

“True–false tests enhance retention relative to rereading” (2021) Journal of Experimental Psychology: Applied

True–false tests enhance retention relative to rereading.
(2021) Journal of Experimental Psychology: Applied, . 

Uner, O., Tekin, E., Roediger, H.L., III

Department of Psychological and Brain Sciences, Washington University in St. Louis, St. Louis, MO, United States

Abstract
Testing with various formats enhances long-term retention of studied information; however, little is known whether true–false tests produce this benefit despite their frequent use in the classroom. We conducted four experiments to explore the retention benefits of true–false tests. College students read passages and reviewed them by answering true–false questions or by restudying correct information from the passages. They then took a criterial test 2 days later that consisted of short-answer questions (Experiments 1 and 2) or short-answer and true–false questions (Experiments 3 and 4). True–false tests enhanced retention compared to rereading correct statements and compared to typing those statements while rereading (the latter in a mini meta-analysis). Evaluating both true and false statements yielded a testing effect on short-answer criterial tests, whereas evaluating only true statements produced a testing effect on true–false criterial tests. Finally, a simple modification that asked students to correct statements they marked as false on true–false tests improved retention of those items when feedback was provided. True–false tests can be an effective and practical learning tool to improve students’ retention of text material. Public Significance Statement—This study shows that true–false quizzes help students retain more information on a later test compared to passive restudy, when students get feedback on their quizzes. Importantly, these quizzes do not only improve memory on later true–false tests, but also on short-answer tests. This study also suggests that a possible method to increase the effectiveness of true–false quizzes is asking students to try correcting true–false questions they consider to be “false.” (PsycInfo Database Record (c) 2021 APA, all rights reserved) © 2021 American Psychological Association

Author Keywords
retrieval practice;  testing effect;  true– false questions

Document Type: Article
Publication Stage: Article in Press
Source: Scopus

“Longitudinal CSF Iron Pathway Proteins in Posthemorrhagic Hydrocephalus: Associations with Ventricle Size and Neurodevelopmental Outcomes” (2021) Annals of Neurology

Longitudinal CSF Iron Pathway Proteins in Posthemorrhagic Hydrocephalus: Associations with Ventricle Size and Neurodevelopmental Outcomes
(2021) Annals of Neurology, . 

Strahle, J.M.a , Mahaney, K.B.b , Morales, D.M.a , Buddhala, C.a , Shannon, C.N.c , Wellons, J.C., IIIc , Kulkarni, A.V.d , Jensen, H.e , Reeder, R.W.e , Holubkov, R.e , Riva-Cambrin, J.K.f , Whitehead, W.E.g , Rozzelle, C.J.h , Tamber, M.i , Pollack, I.F.j , Naftel, R.P.c , Kestle, J.R.W.k , Limbrick, D.D., Jr.a , for the Hydrocephalus Clinical Research Networkl

a Department of Neurosurgery, Washington University St. Louis, St. Louis, MO, United States
b Department of Neurosurgery, Stanford University, Palo Alto, CA, United States
c Department of Neurosurgery, Vanderbilt University Medical Center, Nashville, TN, United States
d Department of Neurosurgery, University of Toronto, Toronto, ON, Canada
e Data Coordinating Center, University of Utah, Salt Lake City, UT, United States
f Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada
g Department of Neurosurgery, Baylor College of Medicine, Houston, TX, United States
h Department of Neurosurgery, University of Alabama – Birmingham, Birmingham, AL, United States
i Department of Surgery, University of British Columbia, Vancouver, BC, Canada
j Department of Neurosurgery, University of Pittsburgh Medical Center, Pittsburgh, PA, United States
k Department of Neurosurgery, University of Utah, Salt Lake City, UT, United States

Abstract
Objective: Iron has been implicated in the pathogenesis of brain injury and hydrocephalus after preterm germinal matrix hemorrhage-intraventricular hemorrhage, however, it is unknown how external or endogenous intraventricular clearance of iron pathway proteins affect the outcome in this group. Methods: This prospective multicenter cohort included patients with posthemorrhagic hydrocephalus (PHH) who underwent (1) temporary and permanent cerebrospinal fluid (CSF) diversion and (2) Bayley Scales of Infant Development-III testing around 2 years of age. CSF proteins in the iron handling pathway were analyzed longitudinally and compared to ventricle size and neurodevelopmental outcomes. Results: Thirty-seven patients met inclusion criteria with a median estimated gestational age at birth of 25 weeks; 65% were boys. Ventricular CSF levels of hemoglobin, iron, total bilirubin, and ferritin decreased between temporary and permanent CSF diversion with no change in CSF levels of ceruloplasmin, transferrin, haptoglobin, and hepcidin. There was an increase in CSF hemopexin during this interval. Larger ventricle size at permanent CSF diversion was associated with elevated CSF ferritin (p = 0.015) and decreased CSF hemopexin (p = 0.007). CSF levels of proteins at temporary CSF diversion were not associated with outcome, however, higher CSF transferrin at permanent CSF diversion was associated with improved cognitive outcome (p = 0.015). Importantly, longitudinal change in CSF iron pathway proteins, ferritin (decrease), and transferrin (increase) were associated with improved cognitive (p = 0.04) and motor (p = 0.03) scores and improved cognitive (p = 0.04), language (p = 0.035), and motor (p = 0.008) scores, respectively. Interpretation: Longitudinal changes in CSF transferrin (increase) and ferritin (decrease) are associated with improved neurodevelopmental outcomes in neonatal PHH, with implications for understanding the pathogenesis of poor outcomes in PHH. ANN NEUROL 2021. © 2021 American Neurological Association.

Funding details
National Institutes of HealthNIHK23 NS075151
01A1, R01 NS110793
National Institute of Neurological Disorders and StrokeNINDS1RC1NS068943
01, 1U01NS10748601A1, CER140313857
Gerber Foundation1692–3638
Hydrocephalus AssociationHA

Document Type: Article
Publication Stage: Article in Press
Source: Scopus